Advances with vaccination against Neisseria meningitidis |
| |
Authors: | Ray Borrow |
| |
Institution: | Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester, UK |
| |
Abstract: | In the last decade, meningococcal serogroup C conjugate vaccination programs have been demonstrated to be hugely successful with a truly impressive public health impact. In sub‐Saharan Africa, with the implementation of an affordable serogroup A conjugate vaccine, it is hoped that a similar public health impact will be demonstrated. Challenges still remain in the quest to develop and implement broadly protective vaccines against serogroup B disease. New, broad coverage vaccines against serogroup B are for the first time becoming available although little is known about their antibody persistence, effectiveness or effect on nasopharyngeal carriage. Enhanced surveillance following any potential vaccine introduction against serogroup B needs to be thoroughly implemented. The future now holds a distinct possibility, globally, for substantially decreasing meningococcal disease, regardless of infecting serogroup. |
| |
Keywords: | meningococcus vaccine polysaccharide conjugate mé ningocoque vaccin polysaccharide conjugué Meningococo vacuna polisacá rido conjugada |
|
|